Your browser doesn't support javascript.
Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan.
Li, Cesheng; Yu, Ding; Wu, Xiao; Liang, Hong; Zhou, Zhijun; Xie, Yong; Li, Taojing; Wu, Junzheng; Lu, Fengping; Feng, Lu; Mao, Min; Lin, Lianzhen; Guo, Huanhuan; Yue, Shenglan; Wang, Feifei; Peng, Yan; Hu, Yong; Wang, Zejun; Yu, Jianhong; Zhang, Yong; Lu, Jia; Ning, Haoran; Yang, Huichuan; Fu, Daoxing; He, Yanlin; Zhou, Dongbo; Du, Tao; Duan, Kai; Dong, Demei; Deng, Kun; Zou, Xia; Zhang, Ya; Zhou, Rong; Gao, Yang; Zhang, Xinxin; Yang, Xiaoming.
  • Li C; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, Wuhan, China.
  • Yu D; Chengdu Rongsheng Pharmaceuticals Co., Ltd, Chengdu, China.
  • Wu X; Beijing Tiantan Biological Products Co., Ltd, Beijing, China.
  • Liang H; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, Wuhan, China.
  • Zhou Z; Chengdu Rongsheng Pharmaceuticals Co., Ltd, Chengdu, China.
  • Xie Y; Beijing Tiantan Biological Products Co., Ltd, Beijing, China.
  • Li T; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, Wuhan, China.
  • Wu J; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, Wuhan, China.
  • Lu F; Beijing Tiantan Biological Products Co., Ltd, Beijing, China.
  • Feng L; Beijing Tiantan Biological Products Co., Ltd, Beijing, China.
  • Mao M; Chengdu Rongsheng Pharmaceuticals Co., Ltd, Chengdu, China.
  • Lin L; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, Wuhan, China.
  • Guo H; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, Wuhan, China.
  • Yue S; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, Wuhan, China.
  • Wang F; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, Wuhan, China.
  • Peng Y; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, Wuhan, China.
  • Hu Y; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, Wuhan, China.
  • Wang Z; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, Wuhan, China.
  • Yu J; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, Wuhan, China.
  • Zhang Y; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, Wuhan, China.
  • Lu J; Wuhan Institute of Biological Products Co. Ltd, Wuhan, China.
  • Ning H; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, Wuhan, China.
  • Yang H; Beijing Tiantan Biological Products Co., Ltd, Beijing, China.
  • Fu D; Wuhan Institute of Biological Products Co. Ltd, Wuhan, China.
  • He Y; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, Wuhan, China.
  • Zhou D; China National Biotec Group Company Limited, Beijing, China.
  • Du T; Beijing Tiantan Biological Products Co., Ltd, Beijing, China.
  • Duan K; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, Wuhan, China.
  • Dong D; Beijing Tiantan Biological Products Co., Ltd, Beijing, China.
  • Deng K; Beijing Tiantan Biological Products Co., Ltd, Beijing, China.
  • Zou X; Beijing Tiantan Biological Products Co., Ltd, Beijing, China.
  • Zhang Y; Wuhan Institute of Biological Products Co. Ltd, Wuhan, China.
  • Zhou R; Beijing Tiantan Biological Products Co., Ltd, Beijing, China.
  • Gao Y; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, Wuhan, China.
  • Zhang X; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, Wuhan, China.
  • Yang X; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd, Wuhan, China.
Nat Commun ; 12(1): 4144, 2021 07 06.
Article in English | MEDLINE | ID: covidwho-1298839
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
To investigate the duration of humoral immune response in convalescent coronavirus disease 2019 (COVID-19) patients, we conduct a 12-month longitudinal study through collecting a total of 1,782 plasma samples from 869 convalescent plasma donors in Wuhan, China and test specific antibody responses. The results show that positive rate of IgG antibody against receptor-binding domain of spike protein (RBD-IgG) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the COVID-19 convalescent plasma donors exceeded 70% for 12 months post diagnosis. The level of RBD-IgG decreases with time, with the titer stabilizing at 64.3% of the initial level by the 9th month. Moreover, male plasma donors produce more RBD-IgG than female, and age of the patients positively correlates with the RBD-IgG titer. A strong positive correlation between RBD-IgG and neutralizing antibody titers is also identified. These results facilitate our understanding of SARS-CoV-2-induced immune memory to promote vaccine and therapy development.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: Receptors, Virus / Immunoglobulin G / Antibodies, Neutralizing / SARS-CoV-2 / Antibodies, Viral Subject: Receptors, Virus / Immunoglobulin G / Antibodies, Neutralizing / SARS-CoV-2 / Antibodies, Viral Type of study: Observational study / Prognostic study Language: English Journal: Nat Commun Year: 2021

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: Receptors, Virus / Immunoglobulin G / Antibodies, Neutralizing / SARS-CoV-2 / Antibodies, Viral Subject: Receptors, Virus / Immunoglobulin G / Antibodies, Neutralizing / SARS-CoV-2 / Antibodies, Viral Type of study: Observational study / Prognostic study Language: English Journal: Nat Commun Year: 2021
...